SCAD : a Registry of Spontaneous Coronary Artery Dissection
Launched by EUROPEAN SOCIETY OF CARDIOLOGY · Sep 13, 2024
Trial Information
Current as of August 26, 2025
Recruiting
Keywords
ClinConnect Summary
The SCAD study is looking at a condition called Spontaneous Coronary Artery Dissection (SCAD), which is a serious heart problem that can happen without the typical risks associated with heart disease. This condition primarily affects younger women and can lead to sudden heart issues. The goal of this trial is to create the first large registry in Europe to gather information about SCAD, helping doctors better understand how to diagnose and treat it. By collecting data from many patients, researchers hope to improve guidelines for treatment and increase awareness among healthcare providers.
To participate in the study, you need to be at least 18 years old and have been diagnosed with SCAD within the last 10 years. You’ll also need to provide consent to join the study. If you decide to participate, your experiences and medical information will contribute to important research that aims to improve care for others with this condition. This is a great opportunity to help advance the understanding of SCAD and potentially benefit future patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient having signed an Informed Consent
- • Patient aged 18 years and over
- • SCAD clinical diagnosis within the past 10 years and available coronary angiographic imagery
- Exclusion Criteria:
- • Patient unwilling or unable to consent
- • Patients with iatrogenic or atherosclerotic coronary dissection
About European Society Of Cardiology
The European Society of Cardiology (ESC) is a leading non-profit organization dedicated to advancing cardiovascular medicine through research, education, and advocacy. With a commitment to improving patient outcomes, the ESC sponsors and conducts clinical trials that explore innovative treatments and interventions in cardiology. By fostering collaboration among healthcare professionals, researchers, and industry partners, the ESC aims to translate scientific discoveries into clinical practice, enhance the understanding of cardiovascular diseases, and ultimately improve the quality of care for patients across Europe and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, , United Kingdom
Vienna, , Austria
Nijmegen, , Netherlands
Odense, , Denmark
Copenhagen, , Denmark
Breda, , Netherlands
Aarhus, , Denmark
Gent, , Belgium
Madrid, , Spain
Bristol, , United Kingdom
Stuttgart, , Germany
Tehran, , Iran, Islamic Republic Of
Sint Niklaas, , Belgium
Leuven, , Belgium
Bodelwyddan, , United Kingdom
Sarajevo, , Bosnia And Herzegovina
Amadora, , Portugal
Braga, , Portugal
Roeselare, , Belgium
Prague, , Czech Republic
Liège, , Belgium
Edegem, , Belgium
Sao Paulo, , Brazil
Banska Bystrica, , Slovakia
Bournemouth, , United Kingdom
Massy, , France
Ashford, , United Kingdom
Nicosia, , Cyprus
Milan, , Italy
Besançon, , France
Wiener Neustadt, , Austria
Vienna, , Austria
Brussels, , Belgium
Monza, , Italy
Singapore, , Singapore
Buenos Aires, , Argentina
Innsbruck, , Austria
Vienna, , Austria
Bruges, , Belgium
Brussels, , Belgium
Genk, , Belgium
Gent, , Belgium
Ottignies, , Belgium
Sao Paulo, , Brazil
São Paulo, , Brazil
Split, , Croatia
Pardubice, , Czech Republic
Hellerup, , Denmark
Clermont Ferrand, , France
Le Coudray, , France
Lyon, , France
Pessac, , France
Bad Rothenfelde, , Germany
Berlin, , Germany
Hamburg, , Germany
Athens, , Greece
Kozani, , Greece
Bergamo, , Italy
Foggia, , Italy
Genoa, , Italy
Mantua, , Italy
Milan, , Italy
Milan, , Italy
Alkmaar, , Netherlands
Auckland, , New Zealand
Bergen, , Norway
Warsaw, , Poland
Tondela, , Portugal
évora, , Portugal
Belgrade, , Serbia
Nis, , Serbia
Leicester, , United Kingdom
London, , United Kingdom
Patients applied
Trial Officials
Adham GHARIEB, PharmD
Study Director
ESC
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported